Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Janus Henderson Group PLC cut its holdings in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 99.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,791 shares of the company's stock after selling 10,505,737 shares during the period. Janus Henderson Group PLC's holdings in Applied Therapeutics were worth $31,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Ground Swell Capital LLC acquired a new position in Applied Therapeutics during the fourth quarter valued at approximately $27,000. Private Advisor Group LLC bought a new position in shares of Applied Therapeutics in the fourth quarter valued at $35,000. SG Americas Securities LLC increased its holdings in Applied Therapeutics by 169.0% during the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock worth $35,000 after buying an additional 25,601 shares during the last quarter. Intech Investment Management LLC raised its position in Applied Therapeutics by 176.1% during the fourth quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock worth $45,000 after acquiring an additional 33,567 shares in the last quarter. Finally, Dark Forest Capital Management LP lifted its stake in Applied Therapeutics by 54.5% in the fourth quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock valued at $46,000 after acquiring an additional 18,949 shares during the last quarter. Institutional investors own 98.31% of the company's stock.

Applied Therapeutics Trading Down 1.8%

APLT stock traded down $0.01 during mid-day trading on Friday, hitting $0.35. 521,475 shares of the company were exchanged, compared to its average volume of 3,132,583. Applied Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $10.62. The stock has a market capitalization of $50.12 million, a PE ratio of -0.22 and a beta of 2.00. The business has a 50 day simple moving average of $0.41 and a 200-day simple moving average of $1.39.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last announced its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million. Equities research analysts expect that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on APLT. Wall Street Zen raised shares of Applied Therapeutics to a "sell" rating in a report on Thursday, May 22nd. Royal Bank of Canada reissued a "sector perform" rating and set a $1.50 price target on shares of Applied Therapeutics in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Applied Therapeutics presently has an average rating of "Hold" and a consensus price target of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.